Iksuda Therapeutics

Developer of antibody drug conjugates for the treatment of solid cancers

placeNewcastle Upon Tyne, England, United Kingdom calendar_todayFounded 2012 groups16 employees language iksuda.com

Registered entities

Social engagement

Social engagement: 4.8K social following, 8 posts in the last 12 months — below the industry typical range.

Investor mix

26 investors on record; lead investors include Mirae Asset Capital Markets, IP Group, North East Technology Fund.

Investor typeCountShare
Venture capital14%
Private equity14%
Bank & private debt28%
Other / undisclosed2285%

Recent activity

22 Jun 2026
Event
BIO International Convention 2026
27 May 2026
Event
Antibody Engineering & Therapeutics Summit
15 May 2026
Event
PEGS 2026
Coming soon